<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02822625</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A00234-47</org_study_id>
    <nct_id>NCT02822625</nct_id>
  </id_info>
  <brief_title>Efficacity of a Standardized Hypnotic Message During the Application of a Qutenza (Capsaicin) 8% Patch</brief_title>
  <acronym>ENHYZA</acronym>
  <official_title>Efficacity of a Standardized Hypnotic Message on Pain Experienced During the Application of a Qutenza (Capsaicin) 8% Patch in Patients With Peripheral Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      QUTENZA® is a skin patch with a high concentration of capsaicin (8%) which is the component
      responsible for spicy peppers. QUTENZA® is indicated for the treatment of peripheral
      neuropathic pain in non-diabetic adults either alone or in combination with other analgesics.
      Acute pain experienced during and after the procedure can be relieved by local cooling
      methods and oral analgesics but the pain remains intense. The hypothesis is that hypnosis via
      a standardized hypnotic message would increase the local tolerance of the treatment when
      applying the patch QUTENZA®. To date, there are no studies that can confirm or refute this
      hypothesis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare pain induced by patch QUTENZA®</measure>
    <time_frame>1 day</time_frame>
    <description>Pain will be evaluated by a numerical scale before, just after, and after installation of the patch</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare anxiety induced by patch QUTENZA®</measure>
    <time_frame>1 day</time_frame>
    <description>Anxiety will be evaluated by a numerical scale before, just after, and after installation of the patch</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the real time of application of the patch</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the number of patients who listened the message in totality.</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the percentage of patients with a sensation of time distortion</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients, followed in the institut and for whom a new application of QUTENZA® is required, will receive standard care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients, followed in the institut and for whom a new application of QUTENZA® is required.
Patients will receive QUTENZA® according to standard procedure with a standardized hypnotic message</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients, followed in the institut and for whom a new application of QUTENZA® is required.
Patients will receive QUTENZA® according to standard procedure with a music therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QUTENZA®</intervention_name>
    <arm_group_label>arm 1</arm_group_label>
    <arm_group_label>arm 2</arm_group_label>
    <arm_group_label>arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>hypnotic message</intervention_name>
    <arm_group_label>arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>music therapy</intervention_name>
    <arm_group_label>arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who have already received at least a QUTENZA® patch

          -  Treatment for patient in failure to conventional treatments for neuropathic pain other
             than diabetics

          -  Age &gt;18 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt;3

          -  Patient must be affiliated to a social security system

          -  Ability to provide written informed consent

          -  Patient's legal capacity to consent to study participation and to understand and
             comply with the requirements of the study

        Exclusion Criteria:

          -  Patient with psychotic disorders

          -  Patient with hearing disorders

          -  Patient not understanding the French language

          -  Age &lt; 18 years

          -  Patient requiring analgesic premedication before applying the patch QUTENZA®

          -  Patient with a history of hypersensitivity to capsaicin or any of the excipients of
             the patch

          -  Patient deprived of liberty or under supervision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CRETINEAU Nathalie, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MERLIN Jean Louis</last_name>
    <phone>00 33 3 83 59 83 07</phone>
    <email>jl.merlin@nancy.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>FERNANDES Laurinda</last_name>
    <phone>0033383598487</phone>
    <email>l.fernandes@nancy.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CRETINEAU Nathalie, MD</last_name>
      <email>n.cretineau@nancy.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>CRETINEAU Nathalie</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>ETIENNE Rémi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>LAURENT Myriam</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>July 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Capsaicin</keyword>
  <keyword>QUTENZA®</keyword>
  <keyword>Hypnosis</keyword>
  <keyword>Peripheral Neuropathic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capsaicin</mesh_term>
    <mesh_term>Hypnotics and Sedatives</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

